TECX

Tectonic is a clinical-stage biotech (GEODe GPCR-biologics platform, lead candidates TX45 and TX2100) with no product revenue in any year 2021–2025 and no approved drugs. As with every pre-commercial biotech, the financial statements describe the burn, not the value — the stock is a call option on clinical readouts that are simply not in the data provided. The 10-K itself frames everything around 'potential safety, efficacy, and regulatory and clinical progress of TX45, TX2100,' i.e. unproven forward events. With zero trial data in front of me, the core value driver is unknowable, so I cannot responsibly stamp a buy or a sell — hence hold at low conviction.

What I can assess — the balance sheet — is genuinely strong and de-risks the near-term. Cash of $254M against a trivial $9.71M of total liabilities (liabilities/equity 0.04x) and only ~$208K of capex means solvency is not the question. Against FY2025 operating cash burn of $60.1M, that cash funds roughly four years — a long runway that lets management reach meaningful clinical milestones without a gun-to-the-head dilutive raise. The share count is tiny (18.8M, up just 0.6% YoY), so the equity structure is clean and the recent capital raise (total assets +70.7%, cash +79.7%) was done from a position of relative strength.